Christopher D Jakubowski Andrew J Plodkowski Jason C Chang Natasha Rekhtman Afsheen Iqbal Paul K Paik Helena A Yu
10.1016/j.cllc.2016.10.001
Clin Lung Cancer
2017 Jan;18(1):e81-e83.
drug toxicity drug-induced pneumonitis egfr-mutant lung cancer egfr-tyrosine kinase inhibitors interstitial lung disease
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/27863924/
Adenocarcinoma / diagnosis Antineoplastic Agents / therapeutic use Drug-Related Side Effects and Adverse Reactions / diagnosis Erlotinib Hydrochloride / adverse effects Lung Diseases, Interstitial / diagnosis Lung Neoplasms / diagnosis Quinazolines / therapeutic use
Adenocarcinoma / diagnosis Antineoplastic Agents / therapeutic use Drug-Related Side Effects and Adverse Reactions / diagnosis Erlotinib Hydrochloride / adverse effects Lung Diseases, Interstitial / diagnosis Lung Neoplasms / diagnosis Quinazolines / therapeutic use Case Reports Adenocarcinoma / drug therapy Afatinib Erlotinib Hydrochloride / therapeutic use Female Genes, erbB-1 / genetics Humans Lung Diseases, Interstitial / etiology Lung Neoplasms / drug therapy Middle Aged Mutation / genetics Neoplasm Metastasis Remission Induction Tomography, X-Ray Computed Withholding Treatment Antineoplastic Agents Quinazolines Afatinib Erlotinib Hydrochloride
PMC5490243
27863924
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer
2017